Identification

Name
Esmolol
Accession Number
DB00187  (APRD00954)
Type
Small Molecule
Groups
Approved
Description

Esmolol (trade name Brevibloc) is a cardioselective beta1 receptor blocker with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages.

Esmolol decreases the force and rate of heart contractions by blocking beta-adrenergic receptors of the sympathetic nervous system, which are found in the heart and other organs of the body. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine.

Structure
Thumb
Synonyms
  • (±)-esmolol
  • (±)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate
  • 3-[4-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-propionic acid methyl ester
  • Methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate
  • methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate
Product Ingredients
IngredientUNIICASInChI Key
Esmolol hydrochlorideV05260LC8D81161-17-3GEKNCWBANDDJJL-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BreviblocInjection10 mg/mLIntravenousBaxter Laboratories1986-12-31Not applicableUs
BreviblocInjection, solution10 mg/mLIntravenousGeneral Injectables & Vaccines2010-07-01Not applicableUs
BreviblocInjection10 mg/mLIntravenousBaxter Laboratories1986-12-31Not applicableUs
BreviblocInjection20 mg/mLIntravenousBaxter Laboratories1986-12-31Not applicableUs
Brevibloc Injection 10mg/mlSolution10 mgIntravenousBaxter Laboratories1996-08-16Not applicableCanada
Brevibloc Injection 250mg/mlLiquid250 mgIntravenousBaxter Laboratories1997-01-172007-06-27Canada
Brevibloc Liq IV 10mg/mlLiquid10 mgIntravenousOhmeda Pharmaceutical Products, Division Of Boc Canada Limited1994-12-311996-09-26Canada
Brevibloc Liq IV 250mg/mlLiquid250 mgIntravenousOhmeda Pharmaceutical Products, Division Of Boc Canada Limited1994-12-311997-08-25Canada
Brevibloc Premixed InjectionSolution10 mgIntravenousBaxter Laboratories2008-09-12Not applicableCanada
EsmololInjection10 mg/mLIntravenousGeneral Injectables & Vaccines2010-04-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Esmolol HydrochlorideInjection10 mg/mLIntravenousGeneral Injectables & Vaccines2015-09-10Not applicableUs
Esmolol HydrochlorideInjection, solution10 mg/mLIntravenousFresenius Kabi2004-11-30Not applicableUs
Esmolol HydrochlorideInjection, solution10 mg/mLIntravenousAmerican Regent2016-01-01Not applicableUs
Esmolol HydrochlorideInjection10 mg/mLIntravenousGeneral Injectables & Vaccines2010-08-01Not applicableUs
Esmolol HydrochlorideInjection, solution10 mg/mLIntravenousGeneral Injectables & Vaccines2012-06-132017-07-01Us
Esmolol HydrochlorideInjection, solution100 mg/10mLIntravenousAuro Medics Pharma Llc2015-07-23Not applicableUs
Esmolol HydrochlorideInjection, solution10 mg/mLIntravenousMylan Institutional2007-05-29Not applicableUs
Categories
UNII
MDY902UXSR
CAS number
81147-92-4
Weight
Average: 295.374
Monoisotopic: 295.178358293
Chemical Formula
C16H25NO4
InChI Key
AQNDDEOPVVGCPG-UHFFFAOYSA-N
InChI
InChI=1S/C16H25NO4/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3
IUPAC Name
methyl 3-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)propanoate
SMILES
COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1

Pharmacology

Indication

For the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention.

Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

Similar to other beta-blockers, esmolol blocks the agonistic effect of the sympathetic neurotransmitters by competing for receptor binding sites. Because it predominantly blocks the beta-1 receptors in cardiac tissue, it is said to be cardioselective. In general, so-called cardioselective beta-blockers are relatively cardioselective; at lower doses they block beta-1 receptors only but begin to block beta-2 receptors as the dose increases. At therapeutic dosages, esmolol does not have intrinsic sympathomimetic activity (ISA) or membrane-stabilizing (quinidine-like) activity. Antiarrhythmic activity is due to blockade of adrenergic stimulation of cardiac pacemaker potentials. In the Vaughan Williams classification of antiarrhythmics, beta-blockers are considered to be class II agents.

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
Absorption

Rapidly absorbed, steady-state blood levels for dosages from 50-300 µg/kg/min (0.05-0.3 mg/kg/mm) are obtained within five minutes.

Volume of distribution
Not Available
Protein binding

55% bound to human plasma protein, while the acid metabolite is 10% bound.

Metabolism

Rapidly metabolized by hydrolysis of the ester linkage, chiefly by the esterases in the cytosol of red blood cells and not by plasma cholinesterases or red cell membrane acetylcholinesterase. Mainly in red blood cells to a free acid metabolite (with 1/1500 the activity of esmolol) and methanol.

Route of elimination

Consistent with the high rate of blood-based metabolism of esmolol hydrochloride, less than 2% of the drug is excreted unchanged in the urine. The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate. Excretion of the acid metabolite is significantly decreased in patients with renal disease, with the elimination half-life increased to about ten-fold that of normals, and plasma levels considerably elevated.

Half life

Rapid distribution half-life of about 2 minutes and an elimination half-life of about 9 minutes. The acid metabolite has an elimination half-life of about 3.7 hours.

Clearance
  • 20 L/kg/hr [Men]
Toxicity

Symptoms of overdose include cardiac arrest, bradycardia, hypotension, electromechanical dissociation and loss of consciousness.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Esmolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Esmolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Esmolol.Experimental, Illicit
AcebutololThe risk or severity of adverse effects can be increased when Esmolol is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Esmolol.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Esmolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Esmolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Esmolol.Approved
AcetohexamideEsmolol may increase the hypoglycemic activities of Acetohexamide.Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Esmolol is combined with Acetylcholine.Approved
AcetyldigitoxinEsmolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinEsmolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Esmolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Esmolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Esmolol.Experimental, Investigational
AlaproclateThe serum concentration of Esmolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Esmolol.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Esmolol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Esmolol.Approved, Illicit
AlfuzosinEsmolol may increase the orthostatic hypotensive activities of Alfuzosin.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Esmolol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Esmolol is combined with Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Esmolol.Experimental
AmbenoniumAmbenonium may increase the bradycardic activities of Esmolol.Approved
Ambroxol acefyllinateEsmolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Esmolol.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Esmolol is combined with Amiloride.Approved
AminophyllineEsmolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Esmolol.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Esmolol is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Esmolol.Approved, Illicit
AmodiaquineThe metabolism of Esmolol can be decreased when combined with Amodiaquine.Approved, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Esmolol.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Esmolol is combined with Amyl Nitrite.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Esmolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Esmolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Esmolol.Approved
ApocyninApocynin may decrease the antihypertensive activities of Esmolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Esmolol is combined with Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Esmolol.Approved, Investigational
ArbutamineEsmolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Esmolol is combined with Arecoline.Experimental
ArformoterolEsmolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Esmolol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Esmolol.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Esmolol.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Esmolol is combined with Atenolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Esmolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Esmolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Esmolol is combined with Azilsartan medoxomil.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Esmolol.Approved, Investigational
BambuterolEsmolol may decrease the bronchodilatory activities of Bambuterol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Esmolol.Experimental
BarbitalBarbital may increase the hypotensive activities of Esmolol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Esmolol.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Esmolol is combined with Benazepril.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Esmolol.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Esmolol is combined with Bendroflumethiazide.Approved
BenorilateBenorilate may decrease the antihypertensive activities of Esmolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Esmolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Esmolol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Esmolol.Approved, Withdrawn
BeractantEsmolol may increase the bradycardic activities of Beractant.Approved
BetaxololThe risk or severity of adverse effects can be increased when Esmolol is combined with Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Esmolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Esmolol.Experimental
BisoprololThe risk or severity of adverse effects can be increased when Esmolol is combined with Bisoprolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Esmolol.Investigational
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Esmolol.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Esmolol.Approved
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Esmolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Esmolol.Investigational
BucindololEsmolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Esmolol.Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Esmolol.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Esmolol is combined with Bumetanide.Approved
BunazosinEsmolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Esmolol.Approved, Investigational
CabergolineEsmolol may increase the vasoconstricting activities of Cabergoline.Approved
CalfactantEsmolol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Esmolol is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Esmolol is combined with Candesartan cilexetil.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Esmolol is combined with Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Esmolol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Esmolol.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Esmolol.Approved
CarbutamideEsmolol may increase the hypoglycemic activities of Carbutamide.Experimental
CarprofenCarprofen may decrease the antihypertensive activities of Esmolol.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Esmolol is combined with Carteolol.Approved
CarvedilolEsmolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Esmolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Esmolol.Approved, Investigational
CeliprololEsmolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
CeritinibEsmolol may increase the bradycardic activities of Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Esmolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Esmolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Esmolol is combined with Chlorothiazide.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Esmolol.Experimental
ChlorpromazineChlorpromazine may increase the hypotensive activities of Esmolol.Approved, Vet Approved
ChlorpropamideEsmolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Esmolol is combined with Chlorthalidone.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Esmolol.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Esmolol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Esmolol.Approved, Investigational
ClenbuterolEsmolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Esmolol is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Esmolol.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Esmolol.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Esmolol.Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Esmolol.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Esmolol.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Esmolol.Vet Approved
CrizotinibEsmolol may increase the bradycardic activities of Crizotinib.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Esmolol.Investigational
CymarinEsmolol may increase the bradycardic activities of Cymarin.Experimental
D-LimoneneD-Limonene may decrease the antihypertensive activities of Esmolol.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Esmolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Esmolol can be increased when it is combined with Dapoxetine.Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Esmolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Esmolol.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Esmolol.Approved
DeslanosideEsmolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Esmolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Vet Approved
DichlorvosDichlorvos may increase the bradycardic activities of Esmolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Esmolol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Esmolol is combined with Diclofenamide.Approved
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Esmolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Esmolol.Approved
DigitoxinEsmolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinEsmolol may increase the bradycardic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Esmolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Esmolol is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Esmolol is combined with Dinutuximab.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Esmolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Esmolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Esmolol.Experimental
DobutamineEsmolol may decrease the bronchodilatory activities of Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Esmolol.Approved
DoxazosinEsmolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DronedaroneDronedarone may increase the bradycardic activities of Esmolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Esmolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Investigational
DuloxetineEsmolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Esmolol.Investigational
DyphyllineEsmolol may decrease the bronchodilatory activities of Dyphylline.Approved
E-6201E-6201 may decrease the antihypertensive activities of Esmolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Esmolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Esmolol.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Esmolol.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Esmolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Esmolol is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Esmolol.Approved
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Esmolol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Esmolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Esmolol is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Esmolol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Esmolol is combined with Eprosartan.Approved
Ergoloid mesylateEsmolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineEsmolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Esmolol is combined with Etacrynic acid.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Esmolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Esmolol.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Esmolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Esmolol.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EtoperidoneThe serum concentration of Esmolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Esmolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Esmolol.Approved, Investigational
exisulindexisulind may decrease the antihypertensive activities of Esmolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Esmolol.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Esmolol is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Esmolol.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Esmolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Esmolol.Approved
FenoterolEsmolol may decrease the bronchodilatory activities of Fenoterol.Approved, Investigational
FentanylFentanyl may increase the bradycardic activities of Esmolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Esmolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Esmolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Esmolol.Experimental
Ferulic acidFerulic acid may decrease the antihypertensive activities of Esmolol.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Esmolol.Approved, Investigational
FingolimodEsmolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Esmolol.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Esmolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Esmolol.Experimental
FluoxetineThe serum concentration of Esmolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Esmolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Esmolol.Approved, Investigational
FormoterolEsmolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Esmolol is combined with Fosinopril.Approved
FurosemideThe risk or severity of adverse effects can be increased when Esmolol is combined with Furosemide.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Esmolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Esmolol.Approved
GitoformateEsmolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideEsmolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideEsmolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideEsmolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideEsmolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneEsmolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideEsmolol may increase the hypoglycemic activities of Glisoxepide.Approved, Investigational
GlyburideEsmolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Esmolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Esmolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Investigational
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Esmolol.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Esmolol.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Esmolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Esmolol.Investigational
HydralazineThe risk or severity of adverse effects can be increased when Esmolol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Esmolol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Esmolol.Approved, Investigational
HydroxychloroquineThe metabolism of Esmolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Esmolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Esmolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Esmolol.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Esmolol.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Esmolol.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Esmolol.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Esmolol.Approved
IndacaterolEsmolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Esmolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Esmolol is combined with Indapamide.Approved
IndobufenIndobufen may decrease the antihypertensive activities of Esmolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Esmolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Esmolol.Withdrawn
IndoraminEsmolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin HumanEsmolol may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkEsmolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Esmolol.Experimental
IrbesartanThe risk or severity of adverse effects can be increased when Esmolol is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Esmolol.Approved
IsoetarineEsmolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Esmolol.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Esmolol.Approved, Investigational, Withdrawn
IsoprenalineEsmolol may decrease the bronchodilatory activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Esmolol is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Esmolol is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Esmolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Esmolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Esmolol is combined with Isradipine.Approved
IvabradineEsmolol may increase the bradycardic activities of Ivabradine.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Esmolol.Experimental
KetoprofenKetoprofen may decrease the antihypertensive activities of Esmolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Esmolol.Approved
LabetalolEsmolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Esmolol.Approved, Investigational
LacosamideEsmolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
Lanatoside CEsmolol may increase the bradycardic activities of Lanatoside C.Experimental
LanreotideEsmolol may increase the bradycardic activities of Lanreotide.Approved
LeflunomideLeflunomide may decrease the antihypertensive activities of Esmolol.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Esmolol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Esmolol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Esmolol.Approved, Investigational
LevodopaEsmolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe serum concentration of Esmolol can be increased when it is combined with Levomilnacipran.Approved
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
LevosalbutamolEsmolol may decrease the bronchodilatory activities of Levosalbutamol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Esmolol.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Esmolol.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Esmolol is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Esmolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Esmolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Esmolol.Experimental
LornoxicamLornoxicam may decrease the antihypertensive activities of Esmolol.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Esmolol is combined with Losartan.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Esmolol.Approved, Investigational
LucinactantEsmolol may increase the bradycardic activities of Lucinactant.Approved, Investigational
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Esmolol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Esmolol.Approved
MalathionMalathion may increase the bradycardic activities of Esmolol.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Esmolol is combined with Mannitol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Esmolol.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Esmolol is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Esmolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Esmolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Esmolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Esmolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Esmolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Esmolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Esmolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Esmolol.Approved, Investigational
MetahexamideEsmolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Esmolol.Investigational, Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Esmolol is combined with Methacholine.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Esmolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Esmolol is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Esmolol.Approved
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Esmolol.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Esmolol is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Esmolol is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Esmolol.Approved, Investigational
MethylergometrineEsmolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Esmolol.Approved
MetildigoxinEsmolol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Esmolol is combined with Metipranolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Esmolol.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Esmolol is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Esmolol is combined with Metoprolol.Approved, Investigational
MidodrineEsmolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Esmolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Esmolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Esmolol is combined with Minoxidil.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Esmolol.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Esmolol is combined with Moexipril.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Esmolol.Experimental
MoricizineMoricizine may increase the hypotensive activities of Esmolol.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Esmolol.Approved, Investigational
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Esmolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Esmolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Esmolol.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Esmolol.Approved
NadololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Esmolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Esmolol.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Esmolol.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Esmolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Esmolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Esmolol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Esmolol is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Esmolol is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Esmolol.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Esmolol is combined with Nicotine.Approved
NifedipineNifedipine may increase the hypotensive activities of Esmolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Esmolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Esmolol.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Esmolol.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Esmolol.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Esmolol is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Esmolol is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Esmolol.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Esmolol.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Esmolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Esmolol is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Esmolol is combined with Nitroprusside.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Esmolol.Approved
OctreotideOctreotide may increase the bradycardic activities of Esmolol.Approved, Investigational
OleandrinEsmolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Esmolol is combined with Olmesartan.Approved, Investigational
OlodaterolEsmolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Esmolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Esmolol.Approved
OrciprenalineEsmolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Esmolol.Vet Approved
OuabainEsmolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Esmolol.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Esmolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Esmolol.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Esmolol.Approved, Vet Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
PapaverineThe risk or severity of adverse effects can be increased when Esmolol is combined with Papaverine.Approved
ParaoxonParaoxon may increase the bradycardic activities of Esmolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Esmolol.Approved
ParoxetineThe serum concentration of Esmolol can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Esmolol.Investigational
PasireotideEsmolol may increase the bradycardic activities of Pasireotide.Approved
PenbutololThe risk or severity of adverse effects can be increased when Esmolol is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Esmolol.Approved, Vet Approved
PerazinePerazine may increase the hypotensive activities of Esmolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Esmolol is combined with Perindopril.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Esmolol.Approved
PeruvosideEsmolol may increase the bradycardic activities of Peruvoside.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Esmolol.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Esmolol.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Esmolol.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Esmolol.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Esmolol.Approved, Vet Approved
PhenylpropanolamineEsmolol may decrease the bronchodilatory activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Esmolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Esmolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Esmolol.Approved, Investigational
PindololThe risk or severity of adverse effects can be increased when Esmolol is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Esmolol.Approved, Investigational
PirbuterolEsmolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Esmolol.Approved, Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Esmolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Esmolol.Experimental
Poractant alfaEsmolol may increase the bradycardic activities of Poractant alfa.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Esmolol.Approved, Investigational
PranoprofenPranoprofen may decrease the antihypertensive activities of Esmolol.Experimental, Investigational
PrazosinEsmolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Esmolol can be decreased when combined with Primaquine.Approved
PrimidonePrimidone may increase the hypotensive activities of Esmolol.Approved, Vet Approved
ProcaterolEsmolol may decrease the bronchodilatory activities of Procaterol.Approved, Investigational
ProchlorperazineProchlorperazine may increase the hypotensive activities of Esmolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Esmolol.Experimental
PromazinePromazine may increase the hypotensive activities of Esmolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Esmolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Esmolol.Approved, Investigational
PropafenoneThe serum concentration of Esmolol can be increased when it is combined with Propafenone.Approved
PropericiazinePropericiazine may increase the hypotensive activities of Esmolol.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Esmolol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Esmolol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Esmolol is combined with Propranolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Esmolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Esmolol.Experimental
ProscillaridinEsmolol may increase the bradycardic activities of Proscillaridin.Experimental
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Esmolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Esmolol.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Esmolol is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Esmolol is combined with Quinapril.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Esmolol.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Esmolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Esmolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Esmolol.Approved
ReserpineReserpine may increase the hypotensive activities of Esmolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Esmolol.Approved, Experimental, Investigational
RifampicinThe serum concentration of Esmolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Esmolol can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Esmolol can be decreased when it is combined with Rifaximin.Approved, Investigational
RiociguatThe risk or severity of adverse effects can be increased when Esmolol is combined with Riociguat.Approved
RisperidoneEsmolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineEsmolol may decrease the bronchodilatory activities of Ritodrine.Approved, Investigational
RivastigmineRivastigmine may increase the bradycardic activities of Esmolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Esmolol.Investigational, Withdrawn
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Esmolol.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Esmolol.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Esmolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Esmolol.Approved
SalbutamolEsmolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Esmolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Esmolol.Approved, Vet Approved
SalmeterolEsmolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Esmolol.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Esmolol.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Esmolol.Approved, Investigational, Vet Approved
SemapimodSemapimod may decrease the antihypertensive activities of Esmolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Esmolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Esmolol.Investigational
SertralineThe serum concentration of Esmolol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Esmolol.Approved, Vet Approved
SilodosinEsmolol may increase the orthostatic hypotensive activities of Silodosin.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Esmolol.Approved
SotalolThe risk or severity of adverse effects can be increased when Esmolol is combined with Sotalol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Esmolol is combined with Spironolactone.Approved
SRT501SRT501 may decrease the antihypertensive activities of Esmolol.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Esmolol.Approved, Investigational
SufentanilEsmolol may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Esmolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Esmolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Esmolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Esmolol.Experimental
TacrineTacrine may increase the bradycardic activities of Esmolol.Investigational, Withdrawn
TamsulosinEsmolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Esmolol.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Esmolol is combined with Telmisartan.Approved, Investigational
TenidapTenidap may decrease the antihypertensive activities of Esmolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Esmolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Esmolol.Vet Approved
TerazosinEsmolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbutalineEsmolol may decrease the bronchodilatory activities of Terbutaline.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Esmolol.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Esmolol.Approved, Investigational, Withdrawn
TheophyllineEsmolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Esmolol.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Esmolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Esmolol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Esmolol.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Esmolol.Approved
ThioridazineThioridazine may increase the hypotensive activities of Esmolol.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Esmolol.Approved
TimololThe risk or severity of adverse effects can be increased when Esmolol is combined with Timolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Esmolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Esmolol.Approved, Investigational
TolazamideEsmolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Esmolol.Approved, Vet Approved
TolbutamideEsmolol may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Esmolol.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Esmolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Esmolol.Approved
TorasemideThe risk or severity of adverse effects can be increased when Esmolol is combined with Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Esmolol is combined with Trandolapril.Approved
TranilastTranilast may decrease the antihypertensive activities of Esmolol.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Esmolol.Approved
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Esmolol.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Esmolol is combined with Triamterene.Approved
TribenosideTribenoside may decrease the antihypertensive activities of Esmolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Esmolol.Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Esmolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Esmolol.Approved, Vet Approved
TrimazosinEsmolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TriptolideTriptolide may decrease the antihypertensive activities of Esmolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Esmolol.Approved
UrapidilEsmolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Esmolol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Esmolol.Approved, Investigational
VareniclineThe risk or severity of adverse effects can be increased when Esmolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Esmolol can be increased when it is combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Esmolol is combined with Verapamil.Approved
VilanterolEsmolol may decrease the bronchodilatory activities of Vilanterol.Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Esmolol.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Esmolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Esmolol can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracZomepirac may decrease the antihypertensive activities of Esmolol.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference
US4593119
General References
Not Available
External Links
Human Metabolome Database
HMDB14333
KEGG Drug
D07916
KEGG Compound
C06980
PubChem Compound
59768
PubChem Substance
46506146
ChemSpider
53916
BindingDB
50404796
ChEBI
88206
ChEMBL
CHEMBL768
Therapeutic Targets Database
DAP000304
PharmGKB
PA449500
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Esmolol
ATC Codes
C07AB09 — Esmolol
AHFS Codes
  • 24:24.00 — Beta-adrenergic Blocking Agents
MSDS
Download (56.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentNeoplasms, Brain1
1, 2Active Not RecruitingTreatmentDiabetic Foot Ulcers (DFU)1
1, 2CompletedSupportive CareOvarian Cysts1
1, 2WithdrawnTreatmentDysautonomia / Traumatic Brain Injury (TBI)1
1, 2WithdrawnTreatmentMyocardial Reperfusion Injury1
2Active Not RecruitingTreatmentShock, Septic1
2CompletedTreatmentHealthy Volunteers / Pharmacokinetics/Dynamics Study1
2CompletedTreatmentNonvalvular Atrial Fibrillation1
2CompletedTreatmentShock, Septic1
2RecruitingTreatmentArterial Hypotension / Shock, Septic / Tachycardia1
2RecruitingTreatmentBloodpressure / Heart Rate1
2RecruitingTreatmentShock, Septic3
2Unknown StatusTreatmentAgeing / Cardiovascular Disease (CVD) / Trauma, Multiple1
2, 3RecruitingTreatmentShock, Septic1
3CompletedTreatmentCerebral Aneurysms / Cerebral Arterial Diseases1
3CompletedTreatmentCoronary Artery Disease1
3RecruitingTreatmentIntracranial Aneurysms / Neoplasms, Intracranial1
3TerminatedTreatmentAnaesthesia therapy1
3TerminatedTreatmentHigh-risk, Non-cardiovascular Surgeries1
4CompletedPreventionPostoperative pain1
4CompletedTreatmentAnesthesia; Adverse Effect / Reflex, Abnormal / Tinnitus, Spontaneous Oto-Acoustic Emission1
4CompletedTreatmentGall Stone Disease1
4CompletedTreatmentHypertensive / Myocardial Ischemia / Tachycardia1
4Not Yet RecruitingScreeningCerebral Oxygen Saturation / Hypotension Drug-Induced1
4RecruitingPreventionIntubations1
4RecruitingPreventionSurgery, Cardiac1
4RecruitingPreventionSurgery, Laparoscopic1
4TerminatedNot AvailableLaminectomy1
4TerminatedPreventionNausea / Occasional Constipation / Pain / Vomiting1
4TerminatedTreatmentAnginal Pain / Cardiac Diseases / Hypertensive / Vascular Diseases1
4Unknown StatusNot AvailableDeviation Septum Nasal1
4Unknown StatusSupportive CareInjection Site Irritation1
4Unknown StatusTreatmentAcute Coronary Syndromes (ACS) / Coronary Artery Disease1
Not AvailableActive Not RecruitingPreventionCancer, Breast / Postoperative pain / Prophylaxis against postoperative nausea and vomiting1
Not AvailableCompletedNot AvailableHypertensive1
Not AvailableCompletedNot AvailableShock, Septic / Tachycardia1
Not AvailableCompletedPreventionPain2
Not AvailableCompletedTreatmentCVA (Cerebrovascular Accident) / Intracerebral Hemorrhage / Intracranial Hemorrhages1
Not AvailableCompletedTreatmentHypertensive1
Not AvailableCompletedTreatmentPain1
Not AvailableCompletedTreatmentSevere Sepsis1
Not AvailableRecruitingTreatmentScheduled Laparoscopic Surgery1
Not AvailableUnknown StatusNot AvailableMyocardial Ischemia1
Not AvailableUnknown StatusBasic ScienceDecrease in Heart Rate Below Baseline Value1
Not AvailableWithdrawnTreatmentSubarachnoid Hemorrhage1

Pharmacoeconomics

Manufacturers
  • Baxter healthcare corp anesthesia critical care
  • App pharmaceuticals llc
  • Bedford laboratories
  • Bioniche pharma usa llc
Packagers
Dosage forms
FormRouteStrength
InjectionIntravenous20 mg/mL
Injection, solutionIntravenous10 mg/mL
SolutionIntravenous10 mg
LiquidIntravenous10 mg
LiquidIntravenous250 mg
InjectionIntravenous10 mg/mL
Injection, solutionIntravenous100 mg/10mL
Prices
Unit descriptionCostUnit
Brevibloc 250 mg/ml ampul13.21USD ml
Brevibloc 10 mg/ml vial2.21USD ml
Brevibloc 20 mg/ml iv bag1.54USD ml
Esmolol hcl 10 mg/ml vial1.26USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2410446No2008-08-262022-01-02Canada
US6528540Yes2001-07-122021-07-12Us
US6310094Yes2001-07-122021-07-12Us
US8835505No2013-03-152033-03-15Us
US8829054No2013-03-152033-03-15Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityVery soluble as hydrochloride saltNot Available
logP1.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.144 mg/mLALOGPS
logP2.02ALOGPS
logP1.82ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.79 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity81.05 m3·mol-1ChemAxon
Polarizability33.68 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7023
Blood Brain Barrier-0.9645
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.6511
P-glycoprotein inhibitor INon-inhibitor0.8625
P-glycoprotein inhibitor IINon-inhibitor0.7171
Renal organic cation transporterNon-inhibitor0.8605
CYP450 2C9 substrateNon-substrate0.8124
CYP450 2D6 substrateSubstrate0.663
CYP450 3A4 substrateNon-substrate0.5869
CYP450 1A2 substrateNon-inhibitor0.864
CYP450 2C9 inhibitorNon-inhibitor0.8789
CYP450 2D6 inhibitorNon-inhibitor0.8806
CYP450 2C19 inhibitorNon-inhibitor0.9585
CYP450 3A4 inhibitorNon-inhibitor0.8495
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9761
Ames testNon AMES toxic0.9066
CarcinogenicityNon-carcinogens0.9519
BiodegradationNot ready biodegradable0.6493
Rat acute toxicity1.9194 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9556
hERG inhibition (predictor II)Non-inhibitor0.774
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-0490000000-55cd388bbf570d69d195

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Not Available
Direct Parent
Phenol ethers
Alternative Parents
Phenoxy compounds / Fatty acid esters / Alkyl aryl ethers / Methyl esters / Secondary alcohols / Amino acids and derivatives / 1,2-aminoalcohols / Monocarboxylic acids and derivatives / Dialkylamines / Organopnictogen compounds
show 3 more
Substituents
Phenoxy compound / Phenol ether / Alkyl aryl ether / Fatty acid ester / Monocyclic benzene moiety / Fatty acyl / Methyl ester / 1,2-aminoalcohol / Secondary alcohol / Amino acid or derivatives
show 17 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
aromatic ether, secondary alcohol, secondary amino compound, methyl ester, ethanolamines (CHEBI:4856)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Jahn P, Eckrich B, Schneidrowski B, Volz-Zang C, Schulte B, Mutschler E, Palm D: Beta 1-adrenoceptor subtype selective antagonism of esmolol and its major metabolite in vitro and in man. Investigations using tricresylphosphate as red blood cell carboxylesterase inhibitor. Arzneimittelforschung. 1995 May;45(5):536-41. [PubMed:7612051]
  3. Volz-Zang C, Eckrich B, Jahn P, Schneidrowski B, Schulte B, Palm D: Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties. Eur J Clin Pharmacol. 1994;46(5):399-404. [PubMed:7957532]
  4. Kirshenbaum JM: Nonthrombolytic intervention in acute myocardial infarction. Am J Cardiol. 1989 Jul 18;64(4):25B-28B. [PubMed:2568748]
  5. Jacobs JR, Maier GW, Rankin JS, Reves JG: Esmolol and left ventricular function in the awake dog. Anesthesiology. 1988 Mar;68(3):373-8. [PubMed:2894187]
  6. Howie MB, Black HA, Zvara D, McSweeney TD, Martin DJ, Coffman JA: Esmolol reduces autonomic hypersensitivity and length of seizures induced by electroconvulsive therapy. Anesth Analg. 1990 Oct;71(4):384-8. [PubMed:1975995]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34